If you have a dog with osteoarthritis, you can pursue stem cell therapy for that dog at a suburban American veterinary specialty clinic with an FDA-recognized product for veterinary use. If you have the exact same osteoarthritis in your own knee, you cannot legally receive an equivalent product from a licensed American physician in the same suburb. The dog gets access to something the human doesn't.
This regulatory asymmetry — approved veterinary regenerative products alongside unapproved human ones — is one of the more striking oddities of modern medicine, and it explains a lot about why Americans travel to Colombia for stem cell therapy. Here's what's actually going on.
The specific regulatory situation
In the United States, the FDA regulates human cell therapies through the biologics framework, requiring extensive safety and efficacy data before market approval. The bar is high. To date, very few cell therapies have received full FDA approval for specific indications (some CAR-T products for cancer, some cord blood products for specific applications).
Veterinary cell therapies fall under a different regulatory pathway administered by the FDA's Center for Veterinary Medicine. The requirements for veterinary product approval — while still substantive — differ meaningfully from human product requirements. Multiple products for canine osteoarthritis, equine soft-tissue injury, and other veterinary applications have achieved marketable status in the US.
The result: veterinarians can offer their patients regenerative treatments that are commercially available, quality-controlled, and administered under professional guidelines. Physicians treating human patients with equivalent conditions cannot.
Why the asymmetry exists
Different regulatory frameworks
Veterinary and human regulatory approval processes are structured differently for historical and practical reasons. This isn't unique to stem cell therapy — many products approved for veterinary use don't have human equivalents (and vice versa).
Different clinical trial economics
Veterinary clinical trials are typically smaller, faster, and less expensive than human trials for the same conditions. This has enabled veterinary regenerative products to reach market while equivalent human products remain in trial stages.
Different indications
Veterinary applications have concentrated on orthopedic and soft-tissue indications where the clinical trial pathway is relatively straightforward. Human medicine has spread across a much broader range of proposed indications, many of which are harder to study rigorously.
Different regulatory culture
Consumer expectations and regulatory posture toward veterinary versus human medicine differ in ways that affect the pace of product development. This isn't necessarily bad — human medicine should have higher safety bars for many reasons — but it creates the specific outcome that veterinary products advance faster.
What veterinary approval actually tells us about human use
An important caveat: veterinary approval does not translate to a green light for human use, and it's not evidence that human trials will succeed. The differences:
- Dogs are not humans. Species-specific differences in physiology, disease mechanisms, and treatment responses are real and sometimes large.
- Veterinary trial endpoints differ. Owner-reported quality of life scores and mobility measurements in dogs don't directly translate to human patient-reported outcomes.
- Long-term follow-up is limited. Dogs live 10-15 years; humans with the same conditions may live 30-50 years post-treatment. Long-term safety questions in humans require longer follow-up.
That said: veterinary approval demonstrates that regenerative products can be developed to quality-controlled market standards, and it demonstrates that certain treatments (particularly for orthopedic conditions) can produce measurable, funded, professionally-endorsed benefit in a related species. This is meaningful evidence context, not proof of human efficacy.
Why this affects Colombian medical tourism
Patients aware of the veterinary approval landscape often reason as follows: "If my dog can get stem cell therapy for arthritis with FDA-recognized products, and I have the same arthritis, but I can't access equivalent treatment in the US — I'll go somewhere I can." Colombia's regenerative-medicine infrastructure serves this population specifically.
This reasoning isn't unreasonable but has limitations worth understanding:
- Colombian regenerative treatments are not the same products as US-approved veterinary treatments. They may be similar in category but differ substantially in specific formulation, dose, and quality control.
- The veterinary evidence supports a treatment category having plausibility for some orthopedic conditions. It doesn't validate any specific product a patient might receive abroad.
- Regulatory approval represents a specific quality bar. Products that would meet that bar are meaningfully different from products that wouldn't. Not every product offered internationally would clear US regulatory review.
How to reason about this if you're considering treatment
The veterinary parallel is a legitimate reason to consider that regenerative treatments can work for some orthopedic conditions. That's important context. It's not a reason to accept any specific claim about any specific treatment offered by any specific clinic.
For patients whose primary interest is orthopedic conditions similar to veterinary indications (osteoarthritis, tendinopathy, some soft-tissue injuries), the veterinary evidence provides real reassurance about category plausibility. Combined with human research showing modest benefit in some of these same conditions, pursuing well-executed treatment at a credible clinic is a reasonable choice.
For patients whose primary interest is conditions not represented in the veterinary approval space (neurodegenerative disease, chronic organ dysfunction, autoimmune conditions, aesthetic applications), the veterinary parallel doesn't apply. Those categories require their own evidence evaluation, which — as covered elsewhere on this site — is highly variable.
The bigger picture
The veterinary-human regulatory asymmetry isn't going to resolve quickly. Human cell therapy trials are expensive and slow. FDA approval of new indications will continue at a measured pace. Meanwhile, veterinary applications will continue to expand.
For the medical tourism industry, this creates ongoing demand from patients who reason (with some justification) that they should have access to at least what their pets can access. Colombian regenerative-medicine clinics range from those offering legitimate investigational treatments to those primarily engaged in marketing. The veterinary parallel supports engaging with the honest end of that market; it doesn't validate engagement with the marketing end.
The specific veterinary applications with the best evidence and market presence are orthopedic — canine osteoarthritis, equine tendon and ligament injuries, and similar. The Colombian human medical applications that most closely mirror those in evidence quality and clinical execution are also orthopedic — knee osteoarthritis (see tennis elbow), rotator cuff and Achilles tendinopathy, hip labral tears, and similar musculoskeletal indications. Pursuing regenerative treatment for these categories is reasoning with the veterinary evidence honestly. Pursuing it for conditions where even veterinary medicine hasn't demonstrated benefit is a different decision.